Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BG2205
- Development stage
- Phase 1
- Lead developer
- Guangzhou Bio-gene Technology
- Modality
- Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BG2205 is an autologous bispecific Chimeric Antigen Receptor (CAR)-T cell therapy developed by Guangzhou Bio-gene Technology. It is designed to target both CD19 and B-cell maturation antigen (BCMA) simultaneously. The drug's mechanism of action involves immunologic cytotoxicity and T lymphocyte replacements, leading to the effective elimination of naive B cells, mature B cells, and plasma cells. This profound depletion of the B-lymphocyte population is intended to induce immune reconstitution and restore normal immune function, making it a potential treatment for autoimmune diseases and certain hematologic malignancies.
- Other names
- CD19-BCMA CAR-T Cell TherapyCD-19-BCMA CAR-T Cell TherapyCD 19-BCMA CAR-T Cell Therapy
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)
Beyond the preview
Go deeper on BG2205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BG2205.